This randomized prospective study will be carried out on 60 adult patients of ASA physical status II and III, scheduled for laparascopic surgeries. After the approval by the Institutional Ethical Committee, written informed consent will be obtained from all the patients before being included in the study.They will be randomly allocated to following groups of  30 each:

•                      Group  A: patients taking amlodipine as antihypertensive medication

•                      Group  B:  Patients taking  telmisartan as antihypertensive medication

All patients will receive Tab.Alprazolam 0.25mg orally, Tab.Ranitidine 150mg and Tab. Metaclopramide 10mg on the night before surgery and 2 hrs prior to surgery. Morrning dose of antihypertensive medication is given. Before arriving at the operation room an18-gauge peripheral venous cannula will be inserted and all patients will be preloaded with 500ml of Lactated Ringer solution. Patients will recieve Inj.midazolam 30mcg/kg.   In the O.R. base line readings of  Heart Rate(HR) , Systolic Blood Pressure(SBP), Diastolic Blood Pressure(DBP), Mean Arterial Pressure(MAP), Oxygen Saturation(Sa02), and  End Tidal CO2(ETCO) will be measured.  Thereafter measurements of HR, SBP, DBP, MAP, ETCO₂ will be taken at intervals of 1, 5 and 10 minutes will be recorded. Patients will be induced with 1% of Inj. Propofol 2mg/kg and depth of anesthesia will be monitored by loss of  following verbal commands. Inj. Vecuronium 0.1mg/kg will be administered. After mask ventilation for three minutes, the appropriate sized airway device will be inserted. Effective ventilation with device wil be defined as a square wave capnogragh trace and bilateral chest movements on manual ventilation. Patients will be maintained with 33% of oxygen in nitrous oxide, isoflurane and intermittent dose of  vecuronium . Perioperative analgesia will be provided with Inj Fentanyl 2 mcg/kg. The tidal volume and respiratory frequency will be adjusted and intermittent positive pressure ventilation (IPPV) will be continued by mechanical ventilator to maintain end tidal carbon dioxide level between 35-45 mm Hg. Pneumoperitonium will be created by insufflation of carbon dioxide and operation table will be tilted 15 degree reverse trendelenburg position.

Intra abdominal pressure will not be not allowed to exceed 14 mm Hg throughout the surgery. Any regurgitation of fluid through the gastric channel or airway tube will be noted.

Heart rate(HR), non-invasive Systolic blood pressure(SBP), Diastolic Blood pressure(DBP), Mean arterial blood pressure (MAP), oxygen saturation (SpO₂), end tidal carbon dioxide(EtCO₂) will be recorded at 1,5 and 10 minutes after insertion of device. After pneumoperitonium at 5,10,15,30,45,60,90 and 120  minutes and just  after removal of device. At the end of surgery residual neuromuscular block will be reversed with appropriate dose of Inj.neostigmine and Inj. glycopyrrolate intravenously. After reversal patients will be monitored in the post anesthesia care area.

Complications such as  incidence of any airway complications caused by supraglottic devices will be managed accordingly.

The study will end after 1 month after all data has been obtained.